Alopecia Areata vs Androgenic Alopecia: Types, Causes & Treatments

Hair loss affects millions of people, but not all hair loss is the same. Two of the most common types — alopecia areata and androgenic alopecia — have fundamentally different causes, patterns, and treatment approaches. Understanding which type you're dealing with is the critical first step toward effective management.

This guide breaks down the key differences between these conditions, explains what causes each one, and outlines the treatment options available in 2026.

What Is Alopecia Areata?

Alopecia areata is an autoimmune condition in which the immune system mistakenly attacks hair follicles, causing hair to fall out — often in small, round patches. It can affect the scalp, eyebrows, eyelashes, beard, and any other area of the body where hair grows.

Key characteristics:

• Sudden onset — patches may appear over days to weeks
• Round or oval bald patches, often smooth and skin-colored
• "Exclamation point" hairs — short, broken hairs that are narrower at the base — at patch edges
• Can occur at any age, though it often begins before age 30
• Affects approximately 2% of the global population at some point in their lifetime

Variants of alopecia areata:

• Alopecia totalis: Complete loss of hair on the scalp
• Alopecia universalis: Complete loss of hair on the entire body
• Ophiasis: Band-like hair loss along the sides and back of the scalp

What Is Androgenic Alopecia?

Androgenic alopecia — commonly known as male-pattern or female-pattern hair loss — is the most common type of hair loss, driven by genetics and hormonal factors. Unlike alopecia areata, it develops gradually over months to years.

In men (male-pattern baldness):

• Typically begins with a receding hairline at the temples
• Progresses to thinning at the crown (vertex)
• May eventually leave only a horseshoe-shaped ring of hair
• Follows the Norwood-Hamilton classification scale
• Affects approximately 50% of men by age 50

In women (female-pattern hair loss):

• Usually presents as diffuse thinning across the top of the scalp
• Hairline typically remains intact
• Follows the Ludwig classification scale
• Often becomes noticeable after menopause, though it can begin earlier
• Affects approximately 40% of women by age 50

Causes: Autoimmune vs. Hormonal

Alopecia areata causes: The immune system targets hair follicles in their active growth phase (anagen), causing them to prematurely enter the resting phase (telogen) and shed. The exact trigger is unknown, but genetic predisposition plays a role — about 20% of people with alopecia areata have a family member with the condition. It's also associated with other autoimmune conditions like thyroid disease, vitiligo, and type 1 diabetes. Stress, infection, or environmental factors may trigger episodes in genetically susceptible individuals.

Androgenic alopecia causes: This condition is driven by the interaction between androgens (particularly dihydrotestosterone, or DHT) and genetically susceptible hair follicles. DHT — a potent form of testosterone created by the enzyme 5-alpha reductase — binds to androgen receptors in hair follicles, causing them to progressively miniaturize. Over time, affected follicles produce thinner, shorter hairs until they eventually stop producing visible hair altogether. Genetic susceptibility is inherited from both parents.

Diagnosis: How to Tell Them Apart

A licensed provider can usually distinguish between these conditions based on:

Pattern of loss: Alopecia areata creates discrete, round patches with clear borders. Androgenic alopecia follows predictable patterns (receding hairline and crown thinning in men; diffuse thinning in women).

Onset speed: Alopecia areata develops rapidly (weeks), while androgenic alopecia progresses slowly (months to years).

Scalp examination: Dermoscopy (a magnified scalp examination) reveals different findings for each condition — exclamation point hairs and yellow dots in alopecia areata versus hair diameter diversity and miniaturized follicles in androgenic alopecia.

Blood work: Providers may order blood tests to check for autoimmune markers, thyroid function, iron levels, and hormonal panels to support diagnosis and rule out other causes.

Treatment Options for Alopecia Areata

Because alopecia areata is an autoimmune condition, treatments focus on modulating the immune response:

Topical corticosteroids: Applied directly to affected areas, these are often the first-line treatment for limited patch-type alopecia areata. They suppress the local immune response to allow hair regrowth.

Intralesional corticosteroid injections: A provider injects corticosteroids directly into bald patches, which can stimulate regrowth in many cases. This is often effective for patients with a small number of patches.

JAK inhibitors: Newer medications like baricitinib (Olumiant®) have received FDA approval for severe alopecia areata. These oral medications block Janus kinase enzymes that are involved in the immune attack on hair follicles, and they've shown significant regrowth in clinical trials.

Topical immunotherapy: For more extensive alopecia areata, providers may use chemicals like DPCP (diphenylcyclopropenone) applied to the scalp to redirect the immune response away from hair follicles.

Minoxidil: While not addressing the autoimmune cause, topical minoxidil may be used as an adjunctive treatment to support hair regrowth.

Treatment Options for Androgenic Alopecia

Androgenic alopecia treatments focus on blocking DHT, stimulating hair follicles, or both:

Finasteride: An oral medication that inhibits 5-alpha reductase, reducing DHT levels by approximately 70%. It is FDA-approved for male-pattern hair loss and has shown consistent efficacy in clinical trials. Women of childbearing age should not take finasteride due to teratogenic risks.

Minoxidil: Available as a topical solution or foam, minoxidil stimulates hair follicles and extends the growth phase of the hair cycle. It is available over the counter and is approved for both men and women.

Dutasteride: A more potent 5-alpha reductase inhibitor than finasteride, dutasteride blocks both type 1 and type 2 isoforms of the enzyme. While not FDA-approved specifically for hair loss, it is prescribed off-label by some providers.

Low-level laser therapy (LLLT): FDA-cleared devices use low-level laser light to stimulate cellular activity in hair follicles. Evidence is modest but positive for some patients.

Platelet-rich plasma (PRP): Concentrated platelets from the patient's own blood are injected into the scalp. Growing evidence supports its use as an adjunctive treatment, though more large-scale studies are needed.

Hair transplantation: For patients with stable hair loss patterns, surgical transplantation of DHT-resistant follicles from the back and sides of the scalp to thinning areas can provide permanent results.

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.